Malignant Mesothelioma

A type of mesothelioma with a tendency to metastasize. Most tumors originate from either the PLEURA or PERITONEUM, tumors may also originate in the PERICARDIUM or testicular tissue. It is associated with ASBESTOS exposure. Somatic mutations identified in WT1, BCL10, CDKN2A, NF2, and BAP1 genes are associated with the malignancy. OMIM: 156240.

Also Known As:

Mesothelioma, Malignant; Malignant Mesotheliomas; Malignant Pleural Mesotheliomas; Mesotheliomas, Malignant; Mesotheliomas, Malignant Pleural; Pleural Mesothelioma, Malignant; Pleural Mesotheliomas, Malignant; Malignant Pleural Mesothelioma; Mesothelioma, Malignant Pleural

Networked: 5227 relevant articles (249 outcomes, 844 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
3.	Mesothelioma
4.	Adenocarcinoma
5.	Ascites

Experts

1.	Pass, Harvey I: 73 articles (09/2021 - 02/2002)
2.	Nakano, Takashi: 71 articles (01/2022 - 09/2006)
3.	Mutti, Luciano: 65 articles (05/2022 - 02/2002)
4.	Carbone, Michele: 56 articles (09/2021 - 02/2002)
5.	Creaney, Jenette: 44 articles (01/2022 - 12/2005)
6.	Opitz, Isabelle: 43 articles (11/2022 - 10/2005)
7.	Kishimoto, Takumi: 43 articles (01/2022 - 04/2003)
8.	Sekido, Yoshitaka: 42 articles (01/2022 - 09/2003)
9.	Bueno, Raphael: 41 articles (04/2021 - 05/2002)
10.	Testa, Joseph R: 40 articles (06/2022 - 01/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Malignant Mesothelioma:

1.	Pemetrexed (MTA)FDA Link 05/01/2012 - "In our institution, the MTA plus CDDP regimen was the first-line treatment, and the GEM plus CDDP regimen was the second-line treatment against peritoneal malignant mesothelioma. " 02/01/2007 - "Pemetrexed is active as first-line treatment of malignant pleural mesothelioma. " 01/01/2007 - "Efficacy of pemetrexed has been demonstrated in malignant pleural mesothelioma. " 04/15/2003 - "This phase II clinical study evaluated the efficacy of pemetrexed for the treatment of malignant pleural mesothelioma (MPM). " 11/01/2020 - "Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901."
2.	Cisplatin (Platino)FDA LinkGeneric 01/01/1991 - "[Remission of malignant pleural mesothelioma using high-dose cisplatin in monochemotherapy]." 01/01/2018 - "Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model." 08/01/2017 - "The present study investigated the effects of SFN on enhancing the anticancer role of cisplatin (cis-dichlorodiammineplatinum; CDDP) in H‑28 malignant mesothelioma cells. " 03/01/2010 - "This study aims to investigate the effect of intrapleural polymeric films containing cisplatin on the local recurrence of malignant pleural mesothelioma in a rat tumour model. " 03/01/2010 - "Intrapleural polymeric films containing cisplatin for malignant pleural mesothelioma in a rat tumour model: a preliminary study."
3.	AsbestosIBA 02/23/2013 - "Malignant mesothelioma is an asbestos-related fatal disease with no effective cure. " 04/02/2010 - "Malignant mesothelioma is an asbestos-related fatal disease with no effective cure. " 01/01/2009 - "There is no effective cure or treatment for any of the lung or pleural asbestos related diseases; malignant mesothelioma has a median survival of just 6-12 months. " 08/01/1995 - "Most malignant mesothelioma cases are associated with pulmonary asbestos body (AB) counts significantly greater than those of the general population. " 05/20/1978 - "A study of the occupational histories of 52 females with malignant mesothelioma and certain of their relatives, carried out to measure the risk of this disorder attributable to indirect asbestos exposure, showed that a significantly greater number of husbands and fathers of cases than of controls worked in asbestos-related industries, and the relative risk for this factor was 10. "
4.	NivolumabIBA 08/01/2020 - "Randomized phase III trials are ongoing to investigate the efficacy of nivolumab in malignant pleural mesothelioma (MPM), but real-world data are still scarce. " 11/22/2023 - "This study aimed to evaluate the cost-effectiveness of nivolumab compared to placebo for relapsed malignant mesotheliomas from the perspective of the Chinese healthcare system. " 11/01/2021 - "Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial." 03/01/2021 - "Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study." 09/15/2019 - "The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. "
5.	PlatinumIBA 04/01/2015 - "In this open-label, single-arm, phase 2 study, participants aged 18 years or older with unresectable, advanced malignant mesothelioma (measurable in accordance with the Response Evaluation Criteria in Solid Tumors [RECIST]), a life expectancy of 3 months or more, an Eastern Cooperative Oncology Group performance status of 2 or less, and who had failed a first-line platinum-based regimen were enrolled at the University Hospital of Siena, Siena, Italy. " 10/01/2013 - "In our open-label, single-arm, phase 2 study, we enrolled patients aged 18 years or older with measurable, unresectable malignant mesothelioma and progressive disease after a first-line platinum-based regimen. " 01/01/2014 - "We report the case of a biopsy proven Malignant Pleural Mesothelioma (MPM) presenting as an anterior mediastinal mass in a platinum miner. " 04/01/2012 - "The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma." 01/01/2017 - "Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma."
6.	IpilimumabIBA 01/01/2022 - "On October 2, 2020, FDA approved nivolumab with ipilimumab as first-line treatment for adult patients with unresectable malignant pleural mesothelioma (MPM). " 11/12/2020 - "The FDA approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. " 12/01/2020 - "Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials." 01/01/2022 - "Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma." 01/01/2021 - "NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma."
7.	Gemcitabine FDA Link 04/01/2003 - "[Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma]." 01/01/1999 - "Impressive remission in a patient with locally advanced malignant pleural mesothelioma treated with gemcitabine." 01/01/2021 - "This study confirms the activity of gemcitabine in treating malignant mesothelioma. " 01/01/2012 - "The aim of our study was to evaluate the influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma (MM). " 02/01/2001 - "No antitumor activity was observed for single-agent gemcitabine in patients with malignant mesothelioma in this multicenter phase II study."
8.	Proteins (Proteins, Gene)FDA Link 03/01/2023 - "The aim of this study is to analyze the prevalence of somatic mutations in BRCA1 and BRCA2 in malignant mesothelioma and their putative impact on protein properties. " 03/01/2023 - "A study of somatic BRCA variants and their putative effect on protein properties in malignant mesothelioma." 06/01/2022 - "Other studies characterized malignant mesothelioma CSCs for the expression of specific genes involved in stemness and the expression of proteins involved in chemoresistance. " 05/01/2018 - "The present study aimed to evaluate the expression of yes-associated protein 1 (YAP1) and tafazzin (TAZ) protein, which are associated with NF2 gene mutations, in malignant mesothelioma (MM) and reactive mesothelial cells (RMCs). " 11/01/2013 - "Genomic studies of malignant pleural mesothelioma (MPM) have recently identified frequent mutations in the BRCA-associated protein 1(BAP1) gene. "
9.	Carboplatin (JM8)FDA LinkGeneric 01/01/1990 - "Thirty-one patients with advanced malignant mesothelioma, previously untreated or having received only one prior cytotoxic regimen, were treated in a prospective, single-arm phase II trial with carboplatin (NSC 241240) at a dose of 150 mg/m2 per day intravenously (IV) for 3 days (450 mg/m2/course). " 01/01/1990 - "Phase II trial of carboplatin in the management of malignant mesothelioma." 01/01/1986 - "Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma." 01/01/1990 - "Carboplatin has modest activity against malignant mesothelioma and, because of its low toxicity, has a role in the management of this disease." 01/01/1990 - "Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma."
10.	Bevacizumab (Avastin)FDA Link 12/01/2017 - "A review of bevacizumab in the treatment of malignant pleural mesothelioma." 01/01/2017 - "Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date." 01/01/2020 - "Studies of bevacizumab and pembrolizumab in the treatment of malignant pleural mesothelioma suggest anticancer efficacy; clinical trial populations are not reflective of real-world patients. " 08/15/2008 - "Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma." 01/01/2022 - "While little progress has been made in malignant pleural mesothelioma diagnosis, bevacizumab at first, then followed by double immunotherapy (nivolumab plus ipilumumab), were all shown to improve survival in large phase III randomized trials. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 02/15/1997 - "Chemotherapy and radiation have not proven effective in controlling malignant mesothelioma. " 08/01/2012 - "Chemotherapy and radiation to port sites independently and in combination were associated with improved overall survival in malignant pleural mesothelioma patients. " 02/01/2006 - "Combining chemotherapy with virotherapy: a novel treatment strategy for malignant pleural mesothelioma." 07/01/2002 - "The efficacy of this chemotherapy regimen in malignant mesothelioma needs to be documented in future trials." 03/01/1998 - "Between June 1984 and September 1994, 337 patients with malignant mesothelioma and no prior chemotherapy were accrued to seven phase II studies conducted by the CALGB which screened the efficacy of 10 treatment regimens or dose levels. "
2.	Therapeutics 07/01/2007 - "Trimodality therapy seems to be the best treatment for malignant pleural mesothelioma (MPM). " 01/01/2023 - "Currently, the efficacy of therapeutics is limited in malignant mesothelioma, and developing more effective therapies is the need of the hour. " 05/17/2006 - "This model mimics the progression of human malignant mesothelioma and it is easy to perform and reproducible; therefore it can be useful to study human MPM biology and evaluate the efficacy of novel therapies." 08/01/2013 - "PET/CT has an established role in the diagnosis and staging and shows promise in therapy planning, therapy response assessment, and providing prognostic information in patients with malignant pleural mesothelioma. " 04/01/2005 - "Despite the desperate struggle for improvement in the therapy of malignant pleural mesothelioma in previous decades, no standard therapy could be established. "
3.	Radiotherapy 01/01/2018 - "Although postoperative radiotherapy (RT) for malignant pleural mesothelioma (MPM) has historically been delivered using 3-dimensional conformal RT (3DCRT) techniques, multiple reports show noteworthy safety and efficacy of the more advanced intensity-modulated RT (IMRT). " 06/01/2019 - "The purpose of this study is to evaluate the safety and efficacy of the multimodality treatment with neoadjuvant intensitymodulated radiotherapy (IMRT) for resectable clinical T1-3N0-1M0 malignant pleural mesothelioma (MPM). " 01/09/2015 - "The surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial) is a suitably powered, multicentre, randomised controlled trial, designed to evaluate the efficacy of prophylactic radiotherapy within 42 days of pleural instrumentation in preventing the development of PTM in MPM. " 12/01/2017 - "The purpose was to assess the efficacy of local radiotherapy in a single fraction of 10Gy in preventing malignant seeding at intervention pleural site in patients with malignant pleural mesothelioma. " 07/01/2015 - "To evaluate the efficacy of prophylactic radiotherapy at intervention sites in patients with malignant pleural mesothelioma (MPM). "
4.	Pneumonectomy (Lung Volume Reduction) 04/01/2012 - "Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma." 06/01/2011 - "The question addressed was whether extrapleural pneumonectomy (EPP) is superior to supportive care in the treatment of patients with malignant pleural mesothelioma (MPM). " 01/01/2017 - "Extrapleural Pneumonectomy Is Not Shown to Be Clinically Effective in the Treatment of Malignant Pleural Mesothelioma." 08/01/2007 - "Extrapleural pneumonectomy (EPP) is an effective treatment of malignant pleural mesothelioma. " 05/05/2004 - "Extrapleural pneumonectomy with perioperative adjuvant treatment is safe and effective procedure for epithelial type malignant pleural mesothelioma."
5.	Immunotherapy 06/27/2021 - "Immunotherapy based on two checkpoint inhibitors (ICI), programmed cell death 1 (PD-1, Nivolumab) and cytotoxic T-lymphocyte 4 (CTLA-4, Ipilimumab), has provided a significant improvement in overall survival for malignant mesothelioma (MM). " 01/01/2023 - "Immunotherapy with anti-PD1/PD-L1 is effective in only a subgroup of patients with malignant pleural mesothelioma (MPM). " 06/01/2017 - "Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma." 01/01/2021 - "Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment." 09/20/2023 - "Objective: To explore and analyze differential expressed genes in malignant pleural mesothelioma (MPM) by bioinformatics method, and to study their prognostic value in MPM and their potential role in immunotherapy. "